Abstract 155P
Background
Increased mean platelet volume (MPV), an early marker of platelet activation has been shown to be associated with the pathophysiology of various cancers. However, studies analyzing the prognostic effect of MPV [Disease free survival (DFS) and Overall survival (OS)] in carcinoma stomach are lacking. This study was done to analyze the effect of MPV on DFS and OS of resectable carcinoma stomach patients.
Methods
Retrospective analysis of the data of 143 consecutively resected gastrectomy patients between 2009- 13 was done. Associations between MPV and Clinicopathological factors were assessed. DFS and OS for 5 years were analyzed using the Kaplan-Meier curve.MPV of 10.5 femtolitres (fl) yielded maximum combined sensitivity and specificity on ROC curve. The area under curve(AUC) for MPV was 0.611. Therefore Preoperative cut-off value of MPV was taken as 10.5 fl. Differences between survival curves were tested for statistical significance using the log-rank test.
Results
Mean OS in the group with preoperative MPV < 10.5 vs > 10.5 was 59.3 vs 41.3 mts (95% CI = 58.81 – 60 vs 37.87 - 44.94; P = <0.0001). Mean OS in the group with postoperative (after one month) of MPV< 10.5 vs > 10.5 was 37.9 vs 29.2 mts (95% CI = 32-43.8vs 27.1- 19.8; P = <0.0001). Mean DFS in the group with preoperative MPV < 10.5 vs > 10.5 was 59.8 mts vs 38.2 mts (95% CI = 59.365-60.26 vs 31.798- 44.732; P = <0.0001). Mean DFS with postoperative (after one month) MPV< 10.5 vs > 10.5 58.0 mts vs 25.9 months (95% CI = 56.629 - 59.4 vs 20.841- 30.959; P = 0.012). These results show that MPV estimation both preoperatively and postoperative has a significant impact on both DFS and OS. And those patients who had increased MPV preoperatively had lower DFS and OS compared to those who had MPV lower at the initial presentation. Also, those patients who had initial high MPV which declined postoperatively after one month also had better DFS and OS compared to those who had persistent elevated MPV.
Conclusions
Hence MPV both preoperative and postoperative (1 month) shows to be a promising predictive factor in resectable carcinoma stomach.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract